Indaco Venture Partners and CDP Venture Capital led a €19m in Valo Therapeutics.

Indaco Venture Partners and CDP Venture Capital, venture capital frims, led a €19m in Valo Therapeutics, an immunotherapy company, with participation from Enea Tech Biomedical, Freeman Road. “We are very excited to secure this investment and be backed by Indaco Venture Partners, via the specialized Biotech fund, and two large Italian Institutional investors, CDP and ENEA Tech e Biomedical. This funding will allow Valo to undertake clinical trials in the South of Italy and Australia. Looking more longer term, this funding will also allow us to scale-up development - an important step towards larger Phase 2 clinical trials,” David Hinton, Valo Chair.